Search for:

Ren Jun Lim

Ren Jun Lim is a principal with Baker McKenzie Wong & Leow. He represents local and international clients in both contentious and non-contentious intellectual property matters. He also advises on a full range of healthcare, as well as consumer goods-related legal and regulatory issues. Ren Jun co-leads Baker McKenzie Wong & Leow's Healthcare as well as Consumer Goods & Retail industry groups. He sits on the Law Society of Singapore IP Committee and on the Executive Committee of the Association of Information Security Professionals. He is also a member of the Vaccines Working Group, Singapore Association of Pharmaceutical Industries, a member of the International Trademark Association, as well as a member of the Regulatory Affairs Professionals Association. Ren Jun is ranked in the Silver tier for Individuals: Enforcement and Litigation and Individuals: Prosecution and Strategy, and a recommended lawyer for Individuals: Transactions by WTR 1000, 2020. He is also listed in Asia IP's Best 50 IP Expert, 2020, recognised as a Rising Star by Managing IP: IP Stars, 2019 and one of Singapore's 70 most influential lawyers aged 40 and under by Singapore Business Review, 2016. Ren Jun was acknowledged by WTR 1000 as a "trademark connoisseur who boasts supplementary knowledge of regulatory issues in the consumer products industry." He was also commended by clients for being "very responsive to enquiries and with a keen eye for detail, he is extremely hands-on. His meticulous and in-depth approach to strategising is key to the excellent outcomes we enjoy."

The Health Sciences Authority is conducting a public consultation from 1 to 31 March 2024 on the proposed amendments to the Health Products (Therapeutic Products) Regulations 2016 on patent declaration.
The proposed amendments are intended to provide clarity to stakeholders on the types of patents that must be considered when making an application for registration of a therapeutic product, and for which the patent declaration regulations apply; and to minimize potential indiscriminate use of the patent declaration mechanism.

The Online Criminal Harms Act (OCHA) was introduced in Parliament on 8 May 2023 and passed on 5 July 2023. It has commenced in part on 1 February 2024. Under the OCHA, five types of government directions may be issued to deal with criminal online activities. These directions can be issued to communicators of criminal content, online service providers, and internet service providers. Provisions on the issuance of codes of practice and directives in partnership with online services will come into force at a later stage.

The Cyber Security Agency has published a consultation paper on the proposed Cybersecurity (Amendment) Bill, which would amend the Cybersecurity Act 2018. The CAB seeks to strengthen the legal framework governing the maintenance of national cybersecurity in Singapore, against the pressing need for legislation to effectively address the fast-developing technological environment.

On 7 February 2024, Enterprise Singapore and the Info-communications Media Development Authority launched the Generative AI Sandbox for small and medium-sized enterprises. Through the sandbox, SMEs will be able to receive funding support to experience Generative AI enterprise solutions over a three-month period. This initiative builds on Singapore’s existing efforts to strengthen the development and ecosystem of AI locally.

On 30 January 2024, the Health Science Authority (HSA) announced it had seized over 1.12 million units of illegal health products and removed over 12,000 listings of illegal health products from local e-commerce and social media platforms in 2023 through targeted operations, intelligence sharing and joint enforcement efforts with local and overseas agencies.
Illegal health products include unregistered or counterfeit health products, as well as products with potent medicinal ingredients or banned substances illegally added to them.

The Infocomm Media Development Authority (IMDA) and AI Verify Foundation have announced the draft Model AI Governance Framework for Generative AI (Framework), which adopts a systematic and balanced approach to addressing concerns posed by generative AI (GenAI) while continuing to facilitate innovation. The Framework expands on the Model AI Governance Framework that covered traditional AI, which was last updated in 2020.

On 18 January 2024, the World Health Organization issued new guidance on the ethics and governance of artificial intelligence for health, focusing on large multimodal models (LMMs). The WHO guidance summarizes the broad applications of LMMs in the healthcare industry and includes recommendations for governments, which have the primary responsibility of setting standards for the development and deployment of LMMs, and their integration and use for public health and medical purposes.